On June 28, 2023, the shares in Promore Pharma AB (the "Company") were given observation status with reference to that the Company had, on the one hand, made the decision to discontinue the ensereptide project and, on the other hand, that the Company's board of directors had assessed that the opportunities to raise the capital needed to develop the Company's program for ropocamptide were limited. The Company had further decided to terminate its key personnel including the Company's CEO and CFO. On September 18, 2023, the observation status was updated with reference to material adverse uncertainty in respect of the Company's financial position, and the existence of any other circumstance that results in substantial uncertainty regarding the issuer or the pricing of its financial instruments. Today, November 29, 2023, the Company published a press release with information that the Company had entered into a letter of intent to acquire all of the shares in PMD Device Solutions AB through a reverse takeover, conditional upon, inter alia, approval by a general meeting of the Company's shareholders and Nasdaq Stockholm AB's decision to admit the Company's shares for continued trading on Nasdaq First North Growth Market. The rules of Nasdaq First North Growth Market state that an issuer may be given observation status if it has been the subject of a reverse take-over or otherwise plans to make or has been subject to an extensive change in its business or organization so that the issuer upon an overall assessment appears to be an entirely new company. With reference to the above, Nasdaq Stockholm AB decides to update the observation status for the shares in Promore Pharma AB (PROMO, ISIN code SE0009947740, order book ID 140251). For further information about this exchange notice please contact Enforcement & Investigations, telephone +46 8 405 70 50. Nasdaq Stockholm AB
© 2023 GlobeNewswire
